



(51) International Patent Classification:

A61K 9/00 (2006.01) C12N 5/0793 (2010.01)
A61K 38/48 (2006.01) C12N 7/01 (2006.01)
A61K 48/00 (2006.01) C12N 9/48 (2006.01)
A61P 25/00 (2006.01) C12N 15/864 (2006.01)

(21) International Application Number:

PCT/US2024/013505

(22) International Filing Date:

30 January 2024 (30.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/482,495 31 January 2023 (31.01.2023) US

(71) Applicant: **THE CHILDREN'S HOSPITAL OF PHILADELPHIA** [US/US]; 3401 Civic Center Boulevard, Philadelphia, Pennsylvania 19146 (US).

(72) Inventors: **DAVIDSON, Beverly**; c/o The Children's Hospital of Philadelphia, 2716 South Street, 15th Floor, Philadelphia, Pennsylvania 19146 (US). **RANUM, Paul**; c/o The Children's Hospital of Philadelphia, 2716 South

Street, 15th Floor, Philadelphia, Pennsylvania 19146 (US). **CHEN, Yonghong**; c/o The Children's Hospital of Philadelphia, 2716 South Street, 15th Floor, Philadelphia, Pennsylvania 19146 (US). **KEISER, Megan S.**; c/o The Children's Hospital of Philadelphia, 2716 South Street, 15th Floor, Philadelphia, Pennsylvania 19146 (US). **TECEDOR, Luis**; c/o The Children's Hospital of Philadelphia, 2716 South Street, 15th Floor, Philadelphia, Pennsylvania 19146 (US).

(74) Agent: **HIGHLANDER, Steven L.**; Parker Highlander PLLC, 1120 S. Capital of Texas Hwy, Building One, Suite 200, Austin, Texas 78746 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: NOVEL GENE THERAPY CONSTRUCT FOR CLN2 DISEASE




FIG. 6

(57) Abstract: Provided herein are methods of expressing a tripeptidyl peptidase 1 (TPP1) in a neuron. Also provided herein is a modified adeno-associated virus (AAV) encoding a TPP1 under the control of a promoter operable in a neuron or ependyma cell, and not in dorsal root ganglia.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))